# A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

> **NCT04623021** · PHASE2 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 104 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Nafamostat Mesilate

## Key facts

- **NCT ID:** NCT04623021
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-25
- **Primary completion:** 2020-12-12
- **Final completion:** 2020-12-12
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623021, "A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04623021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*